Key result
Beta blockers, RAS blockers, and thiazides linked to improved 3-year survival in multimorbid older adults.
Why the study?
Persons with multiple chronic conditions receive multiple guideline-recommended cardiovascular medications to improve mortality, but the longitudinal attributable fraction of these medications on survival and age-related heterogeneity was not established.
What is the longitudinal average attributable fraction of guideline-recommended cardiovascular medications for 3-year survival in older adults with multiple chronic conditions?
Observational (n=8,578)
What is the longitudinal average attributable fraction of guideline-recommended cardiovascular medications for 3-year survival in older adults with multiple chronic conditions?
Effect estimate: average attributable fraction 10.4% (beta blockers), 9.3% (RAS blockers), 7.2% (thiazides)
Guideline-recommended cardiovascular medications, particularly beta blockers and RAS blockers, independently contribute to improved 3-year survival in older adults with multiple chronic conditions.
May support survival benefits of these agents in multimorbid older adults; observational data leaves causal effects and practice change open.
BACKGROUND: Persons with multiple chronic conditions receive multiple guideline-recommended medications to improve outcomes such as mortality. Our objective was to estimate the longitudinal average attributable fraction for 3-year survival of medications for cardiovascular conditions in persons with multiple chronic conditions and to determine whether heterogeneity occurred by age. METHODS: Medicare Current Beneficiary Survey participants (N = 8,578) with two or more chronic conditions, enrolled from 2005 to 2009 with follow-up through 2011, were analyzed. We calculated the longitudinal extension of the average attributable fraction for oral medications (beta blockers, renin-angiotensin system blockers, and thiazide diuretics) indicated for cardiovascular conditions (atrial fibrillation, coronary artery disease, heart failure, and hypertension), on survival adjusted for 18 participant characteristics. Models stratified by age (≤80 and >80 years) were analyzed to determine heterogeneity of both cardiovascular conditions and medications. RESULTS: Heart failure had the greatest average attributable fraction (39%) for mortality. The fractional contributions of beta blockers, renin-angiotensin system blockers, and thiazides to improve survival were 10.4%, 9.3%, and 7.2% respectively. In age-stratified models, of these medications thiazides had a significant contribution to survival only for those aged 80 years or younger. The effects of the remaining medications were similar in both age strata. CONCLUSIONS: Most cardiovascular medications were attributed independently to survival. The two cardiovascular conditions contributing independently to death were heart failure and atrial fibrillation. The medication effects were similar by age except for thiazides that had a significant contribution to survival in persons younger than 80 years.
No takes yet. Share an insight, caveat, or question.
Allore et al. (2016) conducted an observational in Multiple chronic conditions (n=8,578). Oral medications for cardiovascular conditions (beta blockers, renin-angiotensin system blockers, and thiazide diuretics) was evaluated on 3-year survival (average attributable fraction 10.4% (beta blockers), 9.3% (RAS blockers), 7.2% (thiazides)). Beta blockers, renin-angiotensin system blockers, and thiazides contributed 10.4%, 9.3%, and 7.2% respectively to improved 3-year survival in older adults with multiple chronic conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: